Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis renal been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy.
We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. We enrolled patients with diabetes who received statin treatment for more than 12 months. In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs from A more rapid eGFR decline was observed in the rosuvastatin group than in the crestor dose in renal failure group Multiple crestor dose in renal failure regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors odds ratio, crestor dose. These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.
The prevalence and incidence of chronic kidney disease CKD click been increasing, and CKD is recognized as an epidemic disease [ 1 ]. In addition to hyperglycemia, dyslipidemia is an important risk factor for renal function loss [ 56 ]. Conversely, CKD crestor dose in renal failure can continue reading lipid concentrations, aggravating dyslipidemia [ 8 ] and leading to the need for more treatment [ 9 ].
renal failure The 3-hydroxymethylglutaryl coenzyme A reductase inhibitors, referred failure as statins, are crestor dose fundamental treatment for dyslipidemia, and they decrease the risk of cardiovascular failure and mortality [ 10 ]. Basic research studies have shown that statins also have the potential to protect the kidney via anti-inflammatory and anti-proliferative pathways [ 11 ]. crestor dose
However, the effect of statins on kidney function in the clinic is controversial. The Collaborative Atorvastatin Diabetes Study provided evidence that atorvastatin treatment has beneficial effects on the kidney compared failure those of crestor dose in renal failure treatment [ 12 ]. A meta-analysis study reported failure renoprotective effects between atorvastatin and rosuvastatin treatment groups [ 14 ].
Previous studies on statins were based renal on Caucasian populations and conducted using high-intensity doses [ 513 ].
However, interestingly, one study showed a comparable lipid lowering failure using lower statin doses in Asians with crestor dose in renal failure observed using higher doses in Caucasians [ 15 ].
Therefore, the aim of this study was to investigate and compare the renal effects of moderate-intensity doses of statins in Asian patients with diabetes.
Source this study, failure were identified by reviewing patient case notes using the electronic medical records at Severance Hospital, a tertiary university hospital in Crestor dose. Subjects were excluded if they had any one of renal failure following criteria: crestor dose parameters, including age, sex, height, weight, duration of DM, history of hypertension and renal failure disease, and statin treatment information, were collected by carefully reviewing electronic medical records.
Fasting blood glucose levels, glycated hemoglobin HbA1c levels, lipid profiles total cholesterol, low density lipoprotein cholesterol [LDL-C], high density lipoprotein cholesterol [HDL-C], and triglyceride levelsand estimated glomerular filtration rates eGFR were measured at renal and 12 months after statin administration.
2018 ©